AbstractAimTo evaluate medical and surgical treatment of postbariatric hypoglycaemia (PBH) in daily practice.Materials and MethodsRetrospective data were extracted from medical records from four hospitals. PBH was defined by neuroglycopenic symptoms together with a documented glucose <3.0 mmol/L in the postprandial setting after previous bariatric surgery. Data were scored semiquantitatively on efficacy and side effects by two reviewers independently. Duration of efficacy and of use were calculated.ResultsIn total, 120 patients were included with a median follow‐up of 27 months with a mean baseline age of 41 years, total weight loss of 33% and glucose nadir 2.3 mmol/L. Pharmacotherapy consisted of acarbose, diazoxide, short‐ and long‐acting octreotide and glucagon‐like peptide‐1 receptor agonist analogues (liraglutide and semaglutide) with an overall efficacy in 45%‐75% of patients. Combination therapy with two drugs was used by 30 (25%) patients. The addition of a second drug was successful in over half of the patients. Long‐acting octreotide and the glucagon‐like peptide‐1 receptor agonist analogues scored best in terms of efficacy and side effects with a median duration of use of 35 months for octreotide. Finally, 23 (19%) patients were referred for surgical intervention. Efficacy of the surgical procedures, pouch banding, G‐tube placement in remnant stomach and Roux‐en‐Y gastric bypass reversal, pooled together, was 79% with a median duration of initial effect of 13 months.ConclusionsIn daily practice, pharmacotherapy for PBH was successful in half to three quarters of patients. Combination therapy was often of value. One in five patients finally needed a surgical procedure, with overall good results.